Chalcogen Bonded Directly To The Oxazine Ring Patents (Class 544/92)
  • Patent number: 6916808
    Abstract: The use of a compound, comprising formula (I) or a salt, ester, amide of prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: July 12, 2005
    Assignee: Alizyme Therapeutics Limited
    Inventors: Robert Downham, Richard Michael John Palmer, Harold Francis Hodson, Christopher Robert Dunk
  • Patent number: 6908917
    Abstract: This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, Y2, Y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: June 21, 2005
    Assignee: Warner-Lambert Company
    Inventor: Daniel Fred Ortwine
  • Patent number: 6841670
    Abstract: Biphenyl-substituted triazines of the formulae which are notable for high thermal stability, are used as stabilizers for organic polymers to counter damage thereto caused by light, oxygen and heat, as light stabilizers for textile fiber materials and as sunscreens for the human skin.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: January 11, 2005
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Ian John Fletcher, Jürgen Kaschig, Georges Metzger, Dieter Reinehr
  • Publication number: 20040259872
    Abstract: The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.
    Type: Application
    Filed: June 24, 2004
    Publication date: December 23, 2004
    Inventors: Louis S. Crocker, Joseph L. Kukura, Andrew S. Thompson, Christine Stelmach, Steven D. Young
  • Patent number: 6812226
    Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: November 2, 2004
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Nicholas Kindon, Garry Pairaudeau, Bryan Roberts, Stephen Thom
  • Patent number: 6809133
    Abstract: An ultraviolet radiation absorbent for thermoplastic polymer materials such as polyethylene terephthalate or polycarbonate contains cyclic imino ester compound of a specified structure in an amount of over 99.5 weight % and less than 100 weight % and having an acid value in the range of 1×10−3-1 and/or a chlorine ion content in the range of 1×10−1-1×103 ppm.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: October 26, 2004
    Assignees: Takemoto Yushi Kabushiki Kaisha, Teijin DuPont Films Japan Limited
    Inventors: Tatsuhiko Osaki, Tetsuo Ichihashi
  • Patent number: 6806269
    Abstract: 2-Amino-benzoxazinones are identified for use in the treatment of Herpes Simplex Virus.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: October 19, 2004
    Assignee: G. D. Searle & Cop
    Inventors: Masashi Kawanishi, Wataru Takahashi
  • Publication number: 20040192684
    Abstract: The present invention relates to novel ultraviolet light absorbers of the benzoxazinone, oxanilide, benzylidene malonate, quinazoline and benzotriazole classes. The invention also relates to polymer and photographic compositions stabilized against the deleterious effects of light induced degradation which comprise the novel ultraviolet light absorbers.
    Type: Application
    Filed: May 17, 2004
    Publication date: September 30, 2004
    Inventors: Ramanathan Ravichandran, Stephen Daniel Pastor, Deborah Judd, Joseph Edmund Babriarz, Andrew Brian Naughton, Mervin Gale Wood, Anthony David Debellis, Rong Xiong, Robert Edward Detlefsen, Joseph Suhadolnik
  • Publication number: 20040180886
    Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 1, 2004
    Publication date: September 16, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Wiemen Liu, Sanxing Sun, Yancey David Ward, Erick Richard Roush Young
  • Publication number: 20040181061
    Abstract: Oxazin(ethi)one compounds of the formula I: 1
    Type: Application
    Filed: November 12, 2003
    Publication date: September 16, 2004
    Inventors: Joachim Rheinheimer, Andreas Gypser, Ingo Rose, Thomas Grote, Peter Schafer, Frank Schieweck, Eberhard Ammermann, John-Bryan Speakman, Siegfried Strathmann, Gisela Lorenz
  • Publication number: 20040176361
    Abstract: The fused heterocyclic compound of the present invention, which is represented by the formula (I): 1
    Type: Application
    Filed: February 24, 2004
    Publication date: September 9, 2004
    Inventors: Masakazu Fujio, Hiroyuki Satoh, Atsushi Numata, Shinichi Takanashi, Yasuhiro Egi, Ryou Tatsumi
  • Patent number: 6787540
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: September 7, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Patent number: 6774232
    Abstract: The present invention relates to benzoxazinone compounds having a yellow index less than about 0, and a sodium concentration less than about 50 ppm. This invention also relates to a process for preparing these compounds comprising the step of reacting an isatoic anhydride with approximately stoichiometric amounts of an acylating compound, where the isatoic anhydride is purified by re-crystallization or other purification methods.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: August 10, 2004
    Assignee: Cytec Technology Corp.
    Inventor: Asim K. Sarkar
  • Publication number: 20040142928
    Abstract: The present invention provides a compound of formula I 1
    Type: Application
    Filed: December 23, 2003
    Publication date: July 22, 2004
    Inventors: Gordon L. Bundy, Fred L. Ciske, Michael J. Genin, Steven E. Heasley, Scott D. Larsen, Byung Hyun Lee, Paul D. May, John R. Palmer, Mark E. Schnute, Valerie A. Vaillancourt, Atli Thorarensen, Allison J. Wolf, Nancy Anne Wicnienski, David Wilhite
  • Publication number: 20040116420
    Abstract: A pyridine ring-containing benzoxazinone derivative or a pharmaceutically acceptable salt or tautomer thereof represented by general formula (1): 1
    Type: Application
    Filed: December 12, 2003
    Publication date: June 17, 2004
    Inventors: Wataru Takahashi, Naoto Watanabe, Yasushi Saito
  • Publication number: 20040067941
    Abstract: The present invention relates to new compounds of general formula (I), as well as to their physiologically acceptable salts, the procedures for their preparation, the intermediate compounds for obtaining them, the application of the compounds of general formula (I) as medicaments in the prevention and treatment of disorders of the Central nervous System and to the pharmaceutical compositions containing them.
    Type: Application
    Filed: April 8, 2003
    Publication date: April 8, 2004
    Inventors: Antonio Torrens-Jover, Jose Aurelio Castrillo-Perez, Jordi Frigola-Constansa
  • Publication number: 20040058920
    Abstract: The present invention relates to Benzoxazinone-derived compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.
    Type: Application
    Filed: April 4, 2003
    Publication date: March 25, 2004
    Inventors: Antoni Torrens Jover, Jose Aurelio Castrillo Perez, Jordi Frigola Constansa, Josep Mas Prio, Alberto Dordal Zueras, Maria Angeles Fisas Escasany
  • Publication number: 20040053921
    Abstract: Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 24, 2002
    Publication date: March 18, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, Yancey David Ward
  • Patent number: 6683077
    Abstract: A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula I wherein R-R4 are as defined herein, or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: January 27, 2004
    Assignee: G.D. Searle & Co.
    Inventors: Norman Abood, Daniel L. Flynn, Daniel P. Becker, Brian M. Bax, Hui Li, Roger A. Nosal, Lori A. Schretzman, Clara I. Villamil
  • Publication number: 20040006078
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 1, 2002
    Publication date: January 8, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Publication number: 20030232826
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: May 29, 2003
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim Pharmaciuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Publication number: 20030225076
    Abstract: Diarylanines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, C1-6 alkoxy, or NR6OR7; X is OR12, NR13R12, or NR14; inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
    Type: Application
    Filed: September 13, 2002
    Publication date: December 4, 2003
    Inventors: Cathlin Biwersi, Haile Tecle, Joseph Scott Warmus
  • Patent number: 6656934
    Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: December 2, 2003
    Assignee: Alizyme Therapeutics Limited
    Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
  • Publication number: 20030208070
    Abstract: The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.
    Type: Application
    Filed: May 29, 2003
    Publication date: November 6, 2003
    Inventors: Louis S. Crocker, Joseph L. Kukura, Andrew S. Thompson, Christine Stelmach, Steven D. Young
  • Patent number: 6639071
    Abstract: The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: October 28, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Joseph L. Kukura, II, Andrew S. Thompson, Christine Stelmach, Steven D. Young
  • Publication number: 20030191123
    Abstract: The use of a compound comprising formula (I): 1
    Type: Application
    Filed: November 27, 2002
    Publication date: October 9, 2003
    Inventors: Harold Francis Hodson, Robert Downham, Timothy John Mitchell, Beverley Jane Carr, Christopher Robert Dunk, Richard Michael John Palmer
  • Publication number: 20030186972
    Abstract: Novel compounds of formula I: 1
    Type: Application
    Filed: September 9, 2002
    Publication date: October 2, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Charles K. Marlowe, Wenhao Li, Ting Su, Robert M. Scarborough
  • Publication number: 20030176429
    Abstract: The use of a compound, comprising formula (I) or a salt, ester, amide of prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
    Type: Application
    Filed: November 27, 2002
    Publication date: September 18, 2003
    Inventors: Robert Downham, Richard Michael John Palmer, Harold Francis Hodson, Christopher Robert Dunk
  • Publication number: 20030139398
    Abstract: The invention is directed to novel quinazoline and quinazoline-like derivatives of Formula (I): 1
    Type: Application
    Filed: April 5, 2002
    Publication date: July 24, 2003
    Inventors: William J. Hoekstra, Edward C. Lawson, Michael J. Costanzo
  • Publication number: 20030130383
    Abstract: An ultraviolet radiation absorbent for thermoplastic polymer materials such as polyethylene terephthalate or polycarbonate contains cyclic imino ester compound of a specified structure in an amount of over 99.5 weight % and less than 100 weight %, having the melt beginning temperature obtained by melting point measurement in differential thermal analysis within the range of 300-310° C. and/or the weight loss beginning temperature obtained by thermogravimetric measurement within the range of 270-305° C.
    Type: Application
    Filed: November 14, 2002
    Publication date: July 10, 2003
    Inventors: Tatsuhiko Osaki, Tetsuo Ichihashi
  • Publication number: 20030130382
    Abstract: An ultraviolet radiation absorbent for thermoplastic polymer materials such as polyethylene terephthalate or polycarbonate contains cyclic imino ester compound of a specified structure in an amount of over 99.5 weight % and less than 100 weight % and having an acid value in the range of 1×10−3-1 and/or a chlorine ion content in the range of 1×10−1-1×103 ppm.
    Type: Application
    Filed: November 12, 2002
    Publication date: July 10, 2003
    Inventors: Tatsuhiko Osaki, Tetsuo Ichihashi
  • Patent number: 6586452
    Abstract: The present invention relates to novel nodulosporic acid derivatives, which are acaricidal, antiparasitic, insecticidal and anthelmintic agents.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: July 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Thomas Shih, Steven L. Colletti, Michael H. Fisher, Peter T. Meinke, Howard C. H. Kuo, Prasun K. Chakravarty, Matthew J. Wyvratt, Sriram Tyagarajan, Richard Berger
  • Publication number: 20030096992
    Abstract: The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well.
    Type: Application
    Filed: September 20, 2002
    Publication date: May 22, 2003
    Inventors: Joseph N. Bernadino, Doris C. O'Toole, William E. Bay
  • Publication number: 20030092712
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: May 15, 2003
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Patent number: 6541629
    Abstract: The present invention relates to polymer conjugates having the formula: wherein T is a heterocyclic unit which is capable of inhibiting one or more proteolytic enzymes; L is a linking group; [Poly] is a polymeric unit, i indicates the number of said heterocyclic units which comprise said conjugate and has the value of from 1 to 100; z is 0 or 1, said polymer conjugates suitable for use in preventing skin irritation resulting from exposure of the skin to body fluids, inter alia, feces, menstrual fluid. The conjugates of the present invention are useful in diapers, dressings, sanitary napkins, and the like.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: April 1, 2003
    Assignee: The Procter & Gamble Company
    Inventors: Scott Edward Osborne, Todd Laurence Underiner
  • Publication number: 20030040513
    Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.
    Type: Application
    Filed: June 13, 2002
    Publication date: February 27, 2003
    Inventors: Andrew Baxter, Nicholas Kindon, Garry Pairaudeau, Bryan Roberts, Stephen Thom
  • Publication number: 20030022895
    Abstract: A class of compounds for the treatment of viral infections.
    Type: Application
    Filed: January 4, 2002
    Publication date: January 30, 2003
    Applicant: G.D. Searle & Co.
    Inventors: Norman Abood, Daniel L. Flynn, Daniel P. Becker, Brian M. Bax, Hui Li, Roger A. Nosal, Lori A. Schretzman, Clara I. Villamil
  • Patent number: 6509334
    Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, N02, amino, and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 a
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: January 21, 2003
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay E. Wrobel, Horace Fletcher, III, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Publication number: 20030008866
    Abstract: New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Application
    Filed: August 26, 2002
    Publication date: January 9, 2003
    Applicant: Chiron Corporation
    Inventors: John M. Nuss, Xiaohui A. Zhou
  • Publication number: 20020137932
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: March 14, 2001
    Publication date: September 26, 2002
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young
  • Patent number: 6444615
    Abstract: This invention relates to 1-substituted-phenyl-3-substituted-2-thioxo-4,5-imidazolidinediones and 2,4,5-imidazolidinetriones which have activity as herbicides, to compositions which contain these compounds and to methods of use of these compounds. In particular, the present invention pertains to 2-thioxo-4,5-imidazolidinediones or 2,4,5-imidazolidinetriones wherein a 2,4,5,6-tetrasubstituted phenyl ring is linked to the heterocyclic ring.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: September 3, 2002
    Assignee: Dow AgroSciences LLC
    Inventors: Bin Li, Ying Man, Zongjian Zhang, Adam Chi-Tung Hsu
  • Publication number: 20020115664
    Abstract: The instant invention describes a method for crystallizing (−)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one from a solvent and anti-solvent solvent system and producing the crystalline product. The desired final crystal form, Form I, can be produced when using methanol or ethanol. Form II is isolated from 2-propanol and can be converted to the desired crystal form at low drying temperatures, such as between about a temperature of 40° C. and 50° C.
    Type: Application
    Filed: October 19, 2001
    Publication date: August 22, 2002
    Inventors: Louis S. Crocker, William F. Clarke, Joseph L. Kukura, Andrew S. Thompson
  • Patent number: 6436929
    Abstract: The present invention provides compounds which are agonists of the progesterone receptor and have the structures: wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORA or NRBCORA; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; RA is selected from H, amino, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; RC is selected from H or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; Q1 is S, NR7, or CR8R9; R5 is an optionally trisubstitu
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: August 20, 2002
    Assignees: Wyeth, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Andrew Fensome, Eugene A. Terefenko, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Jay E. Wrobel, Mark A. Collins
  • Patent number: 6407101
    Abstract: This invention provides a progesterone receptor antagonist of formula 1 having the structure wherein T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA; RA is hydrogen, alkyl, substituted alky, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R5 is hydrogen, allyl, or substituted alkyl; R6 is hydrogen, alkyl, substituted alkyl, or CORB; RB is hydrogen, alkyl, substituted alkyl, alko, substituted alkoxy, amino
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: June 18, 2002
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Mark A. Collins, Valerie A. Mackner, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Patent number: 6380235
    Abstract: The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R5 are independently selected from H or optionally substituted C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alknyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4 and R5 to from a 5 to 7 membered ring; R1 is selected from H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, substituted alknyl, —COH, or optionally substituted —CO(C1 to C3 alkyl), —CO(aryl), —CO(C1 to C3 alkoxy), or —CO(C1 to C3 aminoalkyl) groups; R2 is selected from H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, C1 to C6 alkoxy, or C1 to C6 aminoalkyl groups; R3 is selected from a trisubstitut
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: April 30, 2002
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Reinhold H. W. Bender, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Patent number: 6380189
    Abstract: A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula I wherein R-R4 are as defined herein, or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: April 30, 2002
    Assignee: G.D. Searle & Co.
    Inventors: Norman Abood, Daniel L. Flynn, Daniel P. Becker, Brian M. Bax, Hui Li, Roger A. Nosal, Lori A. Schretzman, Clara I. Villamil
  • Publication number: 20020049204
    Abstract: This invention provides compounds of Formula (I): 1
    Type: Application
    Filed: September 6, 2001
    Publication date: April 25, 2002
    Inventors: Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay E. Wrobel, Horace Fletcher, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Patent number: 6369056
    Abstract: This invention provides compounds of the formula: wherein: A, B and D are N or CH, with the proviso that A, B and D can not all be CH; R1 and R2 are independent substituents selected from H, CORA, NRBCORA, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or groups; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered spirocyclic or heterocyclic ring; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, or optionally substituted alkyl, or alkenyl, or CORC; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is a substituted benzene ring or a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR5; RF is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RG is H, alkyl, or substituted alkyl; R5 is H or alkyl; Q is O, S, NR6, or CR7R8; R6 is CN, SO2CF3, or optionally substituted alkyl, cyc
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: April 9, 2002
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Arthur A. Santilli, Andrew Fensome, Eugene A. Terefenko, Andrew Q. Viet, Jay E. Wrobel, James P. Edwards, Todd K. Jones, Christopher M. Tegley, Lin Zhi
  • Publication number: 20020040138
    Abstract: The present invention relates to benzoxazinones of formula I: 1
    Type: Application
    Filed: July 31, 2001
    Publication date: April 4, 2002
    Inventors: Mona Patel, Joseph Marian Fortunak
  • Patent number: 6348460
    Abstract: A 1,2,3-thiadiazole derivative represented by general formula (I): [wherein R1 is hydrogen atom, halogen atom, (C1-C6) alkyl, phenyl, etc., R2 is the following group (A) or group (B): (wherein R3 is halogen atom, cyano, etc., R4 is hydrogen atom, halogen atom, cyano, etc., X and Y, same or different, are oxygen atom or sulfur atom, n is 0-3, R5 is hydrogen atom, (C1-C20) alkyl, etc., R6 is (C1-C20) alkyl, (C2-C20) alkenyl, etc., and m is 0-2)]; a plant disease controller containing said compound as active ingredient; and a method for using said controller.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: February 19, 2002
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Kenji Tsubata, Takashi Shimaoka, Tateki Nishida, Kazuhiro Takagi, Koji Baba, Sohkichi Tajima